XNASFRES
Market cap35mUSD
Dec 23, Last price
0.85USD
1D
-24.11%
1Q
-43.33%
IPO
-83.59%
Name
Anpac Bio Medical Science Co Ltd
Chart & Performance
P/E
—
P/S
143.27
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-29.78%
Rev. gr., 5y
16.20%
Revenues
2m
-35.86%
Net income
-15m
L-17.78%
CFO
-8m
L-26.46%
Profile
AnPac Bio-Medical Science Co., Ltd., a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. It also offers physical checkup package services. The company was incorporated in 2010 and is headquartered in Lishui, the People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | ||||||
Revenues | 1,789 -35.86% | 2,789 -6.14% | ||||
Cost of revenue | 85,725 | 105,497 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (83,936) | (102,708) | ||||
NOPBT Margin | ||||||
Operating Taxes | (316) | (183) | ||||
Tax Rate | ||||||
NOPAT | (83,620) | (102,526) | ||||
Net income | (15,132) -17.78% | (18,404) 57.85% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 7,433 | 6,971 | ||||
BB yield | ||||||
| Debt | ||||||
Debt current | 834 | 5,297 | ||||
Long-term debt | 7,452 | |||||
Deferred revenue | ||||||
Other long-term liabilities | (5,422) | 174 | ||||
Net debt | 7,862 | 3,701 | ||||
| Cash flow | ||||||
Cash from operating activities | (8,177) | (11,119) | ||||
CAPEX | (236) | (616) | ||||
Cash from investing activities | (236) | (610) | ||||
Cash from financing activities | 7,346 | 12,935 | ||||
FCF | (81,551) | (104,022) | ||||
| Balance | ||||||
Cash | 269 | 1,452 | ||||
Long term investments | 155 | 145 | ||||
Excess cash | 335 | 1,457 | ||||
Stockholders' equity | (81,026) | (72,806) | ||||
Invested Capital | 81,241 | 78,066 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 191 | 68 | ||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | (83,120) | (102,281) | ||||
EV/EBITDA | ||||||
Interest | 373 | 4,257 | ||||
Interest/NOPBT | ||||||